Diagnostics

Journal Browser

► Journal Browser

Special Issue Editor

Prof. Ram Dickman

E-Mail Website
Guest Editor

Rabin Medical Center, Department Gastroenterol, Neurogastroenterol Service, Beilinson Campus, Petah Tiqwa IL-49100, Israel
Interests: gastroesophageal reflux disease; liver; biopsy chronic cough; dysbiosis; breath tests for carbohydrate intolerance

Special Issue Information

Dear Colleagues,

This Special Issue of Diagnostics is dedicated to novel approaches in the evaluation and treatment of gastrointestinal disorders, including liver disorders, extra esophageal manifestations of GERD, dysbiosis and many more.

Recent years have seen enormous progress in the diagnosis and treatment of gastrointestinal diseases, such as in the development of new technological methods, for example: fibroscan instead of liver biopsy for the evaluation of liver fibrosis in Hepatitis C, endoscopic devices for the treatment of GERD, fecal transplantation of microbiota for the treatment of Clostridium defficile and the use of artificial intelligence to answer clinical questions.

This Special Issue aims to provide a platform for clinicians in the field of gastroenterology to publish their research or up-to-date reviews. We invite papers on novel treatments for GERD, diagnosis of liver diseases and new diagnostic markers for gastric pathologies, among others.

Prof. Ram Dickman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

gastroesophageal reflux disease
liver
biopsy chronic cough
dysbiosis
breath tests for carbohydrate intolerance

Published Papers (2 papers)

Download All Papers

Review

Jump to: Other

13 pages, 263 KiB

Open AccessReview

Advances in Mobile Health for Inflammatory Bowel Disease

by Ellen J. Spartz, Lauren DeDecker, Danny Le, Laleh Jalilian and Berkeley N. Limketkai

Diagnostics 2023, 13(1), 37; https://doi.org/10.3390/diagnostics13010037 - 23 Dec 2022

Cited by 1 | Viewed by 1457

Abstract

Mobile health has the potential to transform the management of chronic illnesses, expanding treatment from a purely clinic-based approach to a more patient-centered delivery of care. For patients with inflammatory bowel disease (IBD), a condition characterized by a relapsing and remitting course, adoption of mobile health strategies can promote improved quality of care delivery and clinical outcomes. Benefits of mobile health applications for IBD include tracking symptoms to guide disease management, coordinating data exchange across clinical care providers, increasing communication between patients and the care team, and providing educational materials to increase patient engagement and satisfaction. In this review, we present the current offerings for telemedicine systems and mobile applications designed for patients with IBD and discuss the potential advantages and limitations of utilizing mobile health in the care of these patients. Full article

(This article belongs to the Special Issue Diagnosis and Management of Gastrointestinal Disorders)

Other

Jump to: Review

7 pages, 3226 KiB

Open AccessInteresting Images

Primary Clear Cell Carcinoma of the Pancreas: A Rare Case Report

by Yoo-Na Kang

Diagnostics 2022, 12(9), 2046; https://doi.org/10.3390/diagnostics12092046 - 24 Aug 2022

Cited by 1 | Viewed by 2191

Abstract

Most pancreatic carcinoma is ductal adenocarcinoma. Primary pancreatic clear cell carcinomas composed almost entirely of clear tumor cells are very rare. We present a case of a 72-year-old man with a pancreatic mass, which was detected on abdominal computed tomography (CT). He had no symptoms and no abnormal findings on physical examination; however, he had a history of hepatitis B, hepatitis C, and hepatocellular carcinoma. He had received anti-viral treatment and radiofrequency ablation twice until 2 years prior. One year prior, follow-up contrast-enhanced abdominal CT revealed a newly developed pancreatic mass. Laparoscopic radical antegrade modular pancreato-splenectomy was performed. An ill-defined white-to-tan firm solid mass was observed in the pancreas, approximately 4.3 cm in diameter. The tumor cells showed >95% clear cell features, with a large round to oval nuclei and abundant clear cytoplasms, and well-defined cell membranes. Immunohistochemical staining revealed that the tumor cells were positive for cytokeratin 7, cytokeratin 19, HNF-1β, MUC-1, and p53. We excluded the possibility of metastatic clear renal cell carcinoma, neuroendocrine carcinoma, perivascular epithelioid cell tumor, malignant melanoma, and sarcoma because of the negativity for vimentin, chromogranin, synaptophysin, and HMB45. Consequently, he was diagnosed as having primary clear cell carcinoma of the pancreas and was treated with postoperative radiotherapy. Two months later, abdominal CT was suspicious for local recurrence at the resection margin. Additional adjuvant FOLFIRINOX chemotherapy was carried out 12 times. The patient is still alive after his third radiofrequency ablation for the newly-developed hepatic mass. Immunohistochemical staining for MUC-1 and HNF-1β, as well as histologic feature is very helpful for the diagnosis of primary pancreatic clear cell carcinoma with imaging methods for metastasis exclusion. Full article

(This article belongs to the Special Issue Diagnosis and Management of Gastrointestinal Disorders)

► Show Figures